Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Allogene Therapeutics (ALLO) EBT Margin: 2021-2025

Historic EBT Margin for Allogene Therapeutics (ALLO) over the last 5 years, with Sep 2025 value amounting to 12,011.34%.

  • Allogene Therapeutics' EBT Margin fell 5315766.00% to 12,011.34% in Q3 2025 from the same period last year, while for Sep 2025 it was 24,862.16%, marking a year-over-year decrease of 75950070.00%. This contributed to the annual value of -1,168,850.00% for FY2024, which is 82436053.00% down from last year.
  • As of Q3 2025, Allogene Therapeutics' EBT Margin stood at 12,011.34%, which was down 36.76% from 18,992.54% recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' EBT Margin ranged from a high of 71,041.98% in Q4 2024 and a low of -375,447.62% during Q4 2023.
  • Moreover, its 3-year median value for EBT Margin was -123,064.79% (2023), whereas its average is -139,008.37%.
  • As far as peak fluctuations go, Allogene Therapeutics' EBT Margin tumbled by 36,014,866bps in 2022, and later surged by 44,648,959bps in 2024.
  • Allogene Therapeutics' EBT Margin (Quarterly) stood at 2.50% in 2021, then slumped by 36,014,866bps to -360,146.15% in 2022, then tumbled by 1,530,147bps to -375,447.62% in 2023, then surged by 44,648,959bps to 71,041.98% in 2024, then crashed by 5,315,766bps to 12,011.34% in 2025.
  • Its EBT Margin was 12,011.34% in Q3 2025, compared to 18,992.54% in Q2 2025 and 39,883.33% in Q1 2025.